.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In July 2026, Indiva’s mix concentrated entirely in Capsules at 100.0% share, with category sales up 9.87% month over month but down 51.63% year over year, while total brand sales declined 53.16% year over year and average price rose 32.97%. With Capsules as both the top category and sole contributor, the brand’s rank in Capsules sat at position 3 in British Columbia, indicating category depth despite a 63.47% two-year sales contraction. The pattern implies a strategic narrowing: higher pricing and a single-category focus are cushioning short-term momentum but amplifying exposure to category-specific demand swings.
The pricing step-up to an average of $32.70 alongside a 9.87% month-over-month Capsules lift and a rank of 3 in British Columbia positions Indiva as a premium-priced, capsule-specialist rather than a diversified player, even as year-over-year brand sales fell 53.16%. With 100.0% of sales in Capsules and a 51.63% year-over-year decline in that category, the trade-off is clear: immediate rank stability comes at the cost of resilience to category downturns. The implication is that sustaining the July 2026 momentum likely requires either reinforcing price-value in Capsules to offset a 63.47% 24‑month drop or reintroducing selective category breadth to reduce volatility.
Competitive Landscape
Indiva sits at #6 in ON Capsules in July 2026, unchanged from #6 year over year, and flat versus three months ago at #6, while its historical peak was #5 in June 2025; in contrast, Aspire held #1 both this year and last year with +11.18% YoY sales, and Glacial Gold moved up from #4 to #2 on +78.08% YoY sales, outpacing Indiva’s static rank position. Meanwhile, Redecan slid from #2 to #3 with -34.70% YoY sales and Tweed dipped from #3 to #4 with -35.28% YoY sales, yet Indiva did not convert those declines into a rank gain, remaining behind Emprise Canada at #5 despite its +37.60% YoY sales. The pattern implies a stall: stability at #6 despite competitor churn suggests Indiva’s share is not compounding, and without a shift that translates category softness above it into rank capture, the ceiling near #5 is likely to persist.
Notable Products
CBG/THC 1:2 Blips Tablets 20-Pack (100mg CBG, 200mg THC) posted the largest month-over-month move in July 2026 at +142.9%, yet it held only rank 3, indicating a surge off a small base rather than leadership displacement. Big Blips THC Tablets 55-Pack (550mg) rose 11.7% and remained at rank 1, while Blips THC Tablets 25-Pack (250mg) in rank 2 inched up 2.4%, and four of the top ten are Capsules SKUs, concentrating share in dose-controlled formats. With Capsules occupying ranks 1 through 4 and only one SKU posting a decline at -2.5%, the mix points to Indiva prioritizing higher-dosage tablet lines over Edibles, with growth driven by potency tiers rather than flavor-led variety.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
